Website construction: China Enterprise Power京ICP备19008112号 PowerBy:300.cn Beijing
About
Immunotech Biopharm Ltd is an innovative technology enterprise specializing in the research and development of immunotherapeutic drugs. It has been recognized as a national high-tech enterprise and has internationally advanced technology and rich research and development experience. Since its establishment in 2006, Immunotech Biopharm Ltd has always adhered to the "Give life a second chance" business philosophy, focusing on scientific research, technological innovation, is committed to the application of immunology, cell biology, genetics and other professional discipline theories, and combined with international cutting-edge technical experience, research and development of immunocellular therapy products for major diseases such as malignant tumors, focusing on the construction of a systematic immune cell product development platform and in line with the GMP standards of individual cell products manufacturing production quality platform. To build a brand leader in the field of cell technology in China.
Immunotech Biopharm Ltd is China's first individualized immunocellular preparations in accordance with the drug registration research and to the State Drug Administration to declare the new drug clinical research approval of the enterprise, over the years to undertake and obtain a number of national ministries and municipal scientific research projects funding, has built a set from theoretical demonstration to experimental research, from in vitro experiments to animal experiments, from safety evaluation to clinical research of the complete research and development system. The core product EAL® is currently the only immune cell product approved to enter the phase II clinical trial of solid tumor treatment, has been in Concord, 301 and other Beijing, Tianjin, Henan, Hebei 14 hospitals carried out clinical trial research, is expected to fill the gap in the field of solid tumor cell therapy, has a milestone significance.
Immunotech Biopharm Ltd's core technology team consists of a senior oncologist with strong professionalism and industry-forward thinking. At present, the research and development team has more than 100 people, in the medical theory knowledge and research and development, technology and testing practice have deep professional foundation and technical experience, the establishment of T-cell immunotherapy drug field of systematic research and development platform, there are a number of immunocellular drugs into the pre-clinical research stage, involving solid tumors and hemas and other treatment areas, some of the research and development results have been declared domestic and international patents. The company plans to complete the second half of 2020 all subjects into the group, and by the first half of 2021 to complete the medium-term data analysis, and to the State Drug Administration to apply for conditional approval for listing, while EAL® expanded indications research work and accelerate the pipeline products pre-clinical research work, to promote the secondary cell immunotherapy industry-wide industry coverage of the strategic layout, for the vast number of tumor patients to provide optimized advanced cell immunotherapy treatment programs to improve their survival status.
Immunotech Biopharm Ltd is located in Beijing's research and development and production center with a total area of more than 7500 square meters, mainly for pre-clinical and clinical research and development of immunocellular products, and to support the initial market demand after the product market, all facilities have been issued by the Beijing Municipal Drug Inspection Institute of clean plant (region) inspection report. For EAL® products six-hour transportation radius, the company plans to set up research and development and production centers in Shanghai, Guangzhou and other places, and then plans to set up production centers in Chengdu, Wuhan, Xi'an and Shenyang and other urban areas, covering densely populated areas of the country, accelerate the progress of clinical trials, and Commit to meet future commercialization needs.
In the future, Immunotech Biopharm Ltd will continue to drive lean development with innovation, in order to firmly establish a business, to believe that the high standards, high quality into quality control, enterprise management, industrial layout and other links, for the vast number of cancer patients to provide safe and high-quality immunotherapy drugs, become China's immune cell treatment drugs for the forerunner and leader. for the benefit of human health.